-
Efficiency in 2025 was pushed by the flexibility to scale operations amid sturdy demand throughout all nuclear finish markets, leading to 18% income development and a 50% improve in complete backlog to $7.3 billion.
-
The Authorities Operations phase secured essential new pricing agreements for naval propulsion and initiated main protection uranium enrichment and high-purity depleted uranium (HPDU) applications.
-
Business development was accelerated by the strategic acquisitions of AOT and Kinectrics, which enabled the corporate to safe its first significant AP1000 engineering contract and broaden its position in CANDU life extensions.
-
Administration attributes the 95% income surge in Business Operations to a mixture of 31% natural development in energy and medical sectors alongside the combination of Kinectrics.
-
Operational success within the medical portfolio reached a $100 million annual income milestone, supported by double-digit development in diagnostic isotopes and actinium gross sales.
-
Strategic positioning as a ‘tremendous service provider provider’ permits the corporate to stay technology-agnostic, offering essential elements and engineering to numerous SMR and large-scale reactor OEMs.
-
The corporate is actively evaluating a bodily growth of its Mount Vernon facility to particularly serve the U.S. business nuclear market, leveraging current heavy-lift infrastructure.
-
2026 steering anticipates high-teens income development, with over half of the Authorities Operations development anticipated from the ramp-up of protection fuels and HPDU contracts.
-
Business Operations are projected to attain 25% development in 2026, pushed by low double-digit good points in nuclear energy and high-teens development within the medical isotopes enterprise.
-
Administration expects a 100 foundation level margin growth in Business Operations for 2026 as income scales and the enterprise combine normalizes following current acquisitions.
-
The 2026 monetary framework assumes a barely larger tax fee of roughly 22% attributable to a larger proportion of worldwide earnings from the increasing Kinectrics and business energy companies.
-
Capital expenditures are deliberate at roughly 6% of gross sales to construct out capability for anticipated long-term demand in each the protection and business nuclear sectors.
-
Authorities Operations margins are anticipated to be barely decrease in 2026 as a result of ‘preliminary revenue recognition’ section of recent large-scale applications which carry larger preliminary execution dangers.
-
The corporate efficiently executed a $1.25 billion convertible debt providing with a 0% coupon to optimize its stability sheet and improve liquidity for future M&A and natural investments.
-
Administration famous that 2026 earnings might be extra back-half weighted than normal, with roughly 55% of full-year EBITDA anticipated within the second half attributable to program timing and blend.
-
The Tech-99 medical product stays in a ‘grilling final mile’ of growth attributable to product high quality and filtration points, with no income from this product included within the 2026 steering.
